Hypericin-enhanced argon laser photocoagulation for subfoveal choroidal neovascular membrane in age-related macular degeneration: A pilot study

European Journal of Ophthalmology

Volumn 16, Issue 1, 2006, Pages 119-128

  Sobaci, Güngör ^a   Bayraktar, M Z ^a   Karslioglu Y ^a   Durukan, A H ^a   Hurmeric V ^a   Aykas S ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Age related macular degeneration; Argon laser photocoagulation; Choroidal neovascular membrane; Hypericin

Indexed keywords

HYPERICIN;

ADULT; AGED; ARGON LASER; ARTICLE; CHOROID CAPILLARY LAYER; CLINICAL ARTICLE; COST OF ILLNESS; DRUG EFFICACY; DRUG SAFETY; ENUCLEATION; EVISCERATION; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LASER COAGULATION; MAINTENANCE THERAPY; MALE; PARESTHESIA; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; PHOTOTOXICITY; PIGMENT DISORDER; PIGMENT EPITHELIUM; PILOT STUDY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RUPTURE; SINGLE DRUG DOSE; STOMACH IRRITATION; SUBRETINAL NEOVASCULARIZATION; TABLET; TECHNIQUE; TREATMENT INDICATION; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 33645547432     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/EJO.2008.1371     Document Type: Article

References (33)

1. Meads C, Salas C, Roberts T, Moore D, Fry-Smith A, Hyde C. Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess 2003; 7: 1-108.
2. Agostinis P, Vantieghem A, Merlevede W, de Witte PAM. Hypericin in cancer treatment. More light on the way. IJBCB 2000; 34: 221-41.
3. Obermuller RA, Hohenthanner K, Falk H. Toward hypericin-derived potential photodynamic therapy agents. Photochem Photobiol 2001; 74: 211-5.
4. Muldner H, Zoller M. Antidepressive effect of a Hypericum extract standardized to an active hypericine complex. Biochemical and clinical studies. Arzneimittelforschung 1984; 34: 918-20.
5. Woelk H, Burkard G, Grunwald J. Benefits and risks of the hypericum extract LI 160: drug monitoring study with 3250 patients. J Geriatr Psychiatry Neurol 1994; 7 (Suppl): S34-38.
6. Chen B, Xu Y, Roskams T, et al. Efficacy of antitumoral photodynamic therapy with hypericin: relationship between biodistribution and photodynamic effects in the RIF-1 mouse tumor model. Int J Cancer 2001; 93: 275-82.
7. Kimura H, Harris MS, Sakamoto T, et al. Hypericin inhibits choroidal endothelial cell proliferation and cord formation in vitro. Curr Eye Res 1997; 16: 967-72.
8. Blank M, Kostenich G, Lavie G, Kimel S, Keisari Y, Orenstein A Wavelength-dependent properties of photodynamic therapy using hypericin in vitro and in an animal model. Photochem Photobiol 2002; 76: 335-40.
9. Blank M, Lavie G, Mandel M, et al. Antimetastatic activity of the photodynamic agent in the dark. Int J Cancer 2004; 111: 596-603.
10. Kubin A, Alth G, Jindra R, Jessner G, Ebermann R. Wavelength-dependent photoresponse of biological and aqueous model systems using the photodynamic plant pigment hypericin. J Photochem Photobiol B 1996; 36: 103-8.
11. Kerb R, Brockmoller J, Staffeldt B, Ploch M, Roots I. Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin. Antimicrob Agents Chemother 1996; 40: 2087-93.
12. Brockmoller J, Reum T, Bauer S, Kerb R, Hubner WD, Roots I. Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry 1997; 30 (Suppl): S94-301.
13. Sharma S, Brown GC, Brown MM, Hollands H, Shah GK. The cost-effectiveness of photodynamic therapy for fellow eye with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2001; 108: 2051-9.
14. Woodburn KW, Engelman CJ, Blumenkranz MS. Photodynamic therapy for choroidal neovascularization. A review. Retina 2002; 22: 391-405.
15. Obana A, Gohto Y, Nishiguchi K, Miki T, Nishi S, Asada A. A retrospective pilot study of indocyanine green enhanced diode laser photocoagulation for subfoveal choroidal neovascularization associated with age-related macular degeneration. Jpn J Ophthalmol 2000; 44: 668-76.
16. Macular Photocoagulation Study Group. Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration. The influence of initial lesion size and initial VA. Arch Ophthalmol 1994; 112: 480-8.
17. Coscas G, Soubrane G, Ramahefasolo C, Fardeau C. Perifoveal laser treatment for subfoveal choroidal new vessels in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1991; 109: 1258-65.
18. Kang BY, Chung SW, Kim TS. Inhibition of interleukin-12 production in lipopolysaccharide-activated mouse macrophages by hypericin, an active component of Hypericum perforatum. Planta Med 2001; 67: 364-6.
19. Hudson JB, Lopez-Bazzocchi I, Towers GH. Antiviral activities of hypericin. Antiviral Res 1991; 15: 101-12.
20. Blank M, Mandel M, Hazan S, Keisari Y, Lavie G. Anticancer activation of hypericin in the dark. Photochem Photobiol 2001; 74: 120-5.
21. Prince AM, Pascual D, Meruelo D, et al. Strategies for evaluation of enveloped virus inactivation in red cell concentrate using hypericin. Photochem Photobiol 2000; 71: 188-95.
22. Gulick RM, McAuliffe V, Holden-Wiltse J, et al. Phase I studies of hypericin, the active compound in St. John's Wort, as an antiretroviral agent in HIV-infected adults. AIDS Clinical Trials Group Protocols 150 and 258. Ann Intern Med 1999; 130: 510-4.
23. Schempp CM, Winghofer B, Langheinrich M, Schopf E, Simon JC. Hypericin levels in human serum and interstitial skin blister fluid after oral single-dose and steady-state administration of Hypericum perforatum extract (St. John's wort). Skin Pharmacol Appl Skin Physiol 1999; 12: 299-304.
24. Markowitz JS, DeVane CL, Boulton DW, Carson SW, Nahas Z, Risch SC. Effect of St. John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci 2000; 66: PL133-9.
25. Schey KL, Patat S, Chignell CF, Datillo M, Wang RH, Roberts JE. Photo-oxidation of lens alpha-crystallin by hypericin (active ingredient in St. John's wort). Photochem Photobiol 2000; 72: 200-3.
26. Harris MS, Sakamoto T, Kimura H, et al. Hypericin inhibits cell growth and induces apoptosis in retinal pigment epithelial cells: possible involvement of protein kinase C. Curr Eye Res 1996; 15: 255-62.
27. Fox E, Murphy RF, McCully CL, Adamson PC. Plasma pharmacokinetics and cerebrospinal fluid penetration of hypericin in nonhuman primates. Cancer Chemother Pharmacol 2001; 47: 41-4.
28. Sobaci G, Güven T, ?lker S, Yel M. An investigation of the effects of photothrombosis and photocoagulation on corneal neovascularization. Ann Ophthalmol 1998; 30: 388-91.
29. Solar P, Cavarga I, Hofmanova J, et al. Effect of acetazolamide on hypericin phototoxicity. Planta Med 2002; 68: 658-60.
30. Mirossay A, Mirosay L, Sarissky M, Papp P, Mojsis J. Modulation of the phototoxic effect of hypericin in human leukemia CEM cell line by N-ethylmaleimide, amiloride and omeprazole. Physiol Res 2002; 51: 641-4.
31. Hadjur C, Richard MJ, Parat MO, Jardon P, Favier A. Photodynamic effects of hypericin on lipid peroxidation and antioxidant status in melanoma cells. Photochem Photobiol 1996; 64: 375-81.
32. Uzdensky AB, Lani V, Ma LW, Moan J. Photobleaching of hypericin bound to human serum albumin, cultured adenocarcinoma cells and nude mice skin. Photochem Photobiol 2002; 76: 320-8.
33. D'Hallevin MA, de Vitte PAM, Waelkens E, Merlevede W, Baert L. Fluorescence detection of flat bladder carcinoma in situ after intravesical instillation of hypericin. J Urol 2000; 164: 349-51.